Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2021-05-19 Interim / Quarterly Rep…
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Interim / Quarterly Report Classification · 100% confidence The document is a Form 6-K filed by XTL Biopharmaceuticals Ltd., a foreign private issuer, reporting financial results for the three months ended March 31, 2021. It includes detailed financial statements such as consolidated statements of financial position and comprehensive income, restatement explanations, and management commentary on financial performance and business outlook. The document is not merely an announcement of a report but contains substantive financial data and analysis for a quarterly period. Form 6-K is typically used by foreign private issuers to report interim financial results and other material information. Therefore, this filing corresponds to an Interim / Quarterly Report (IR).
2021-05-19 English
AMENDMENT NO. 1 TO FORM 20-F
Annual Report FY 2020
2021-05-19 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, XTL Biopharmaceuticals Ltd., submitted to the SEC. It announces the company's intention to restate its financial statements for the year ended December 31, 2020, by amending its previously filed Form 20-F. The document discusses the restatement reason, the classification of warrants, and plans to file an F-3 Registration Statement. It does not contain the full annual report or detailed financial statements but is an announcement related to financial reporting and regulatory compliance. Form 6-K filings are typically periodic reports submitted by foreign private issuers to disclose material information. Given the content and nature, this document fits best under Regulatory Filings (RNS) as it is a regulatory announcement and not the full annual report or audit report itself.
2021-05-19 English
results of the Extraordinary General Meeting of shareholders of the Company, Monday, April 5, 2021
AGM Information Classification · 98% confidence The document is explicitly titled "Form 6-K, Report of Foreign Private Issuer" filed with the SEC for the month of April 2021. The content announces the results of an "Extraordinary General Meeting of shareholders" held on April 5, 2021, specifically detailing the re-election of a director. Since the document reports the official results of a shareholder vote from a general meeting, the most appropriate classification among the provided options is AGM-R (AGM Information), as EGMs often fall under the broader category of shareholder meetings/resolutions, or DVA (Declaration of Voting Results & Voting Rights Announcements). Given the content is the *result* of the vote, DVA is highly specific. However, AGM-R covers materials shared during the Annual General Meeting, and while this is an EGM, the core function is reporting meeting outcomes. Since DVA specifically covers 'Official results from shareholder votes at any general meeting (AGM or EGM)', DVA is the most precise fit for reporting the outcome of the vote.
2021-04-05 English
results of the Extraordinary General Meeting of shareholders of the Company, Monday, April 5, 2021
Report Publication Announcement Classification · 95% confidence The document is a short regulatory filing (2,181 characters) from XTL Biopharmaceuticals Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on' followed by a reference to a PDF file (ea139019-6k_xtlbiopharmaEDGAR1_isa.pdf). Per the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, and it serves as a general regulatory notification. FY 2020
2021-04-05 English
REPORT OF FOREIGN PRIVATE ISSUER
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It announces the results of an Extraordinary General Meeting (EGM) where a shareholder vote took place to re-elect an external director. The content focuses on the voting results of a shareholder meeting rather than the full annual report, financial statements, or detailed management discussion. The document length is 3408 characters, which is relatively short and primarily contains an announcement of voting results. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2021-04-05 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.